AI Article Synopsis

  • Esophageal candidiasis (EC) is a common infection of the esophagus, especially in immunocompromised individuals like those with HIV/AIDS or undergoing chemotherapy.
  • Symptoms include pain and difficulty swallowing, often accompanied by a white, plaque-like appearance in the throat during examination.
  • Diagnosis involves endoscopy and biopsy, while treatment typically consists of systemic antifungal medications; prognosis is generally good despite some potential complications.

Article Abstract

Esophageal candidiasis (EC) is the most common type of infectious esophagitis. In the gastrointestinal tract, the esophagus is the second most susceptible to candida infection, only after the oropharynx. Immunocompromised patients are most at risk, including patients with HIV/AIDS, leukemia, diabetics, and those who are receiving corticosteroids, radiation, and chemotherapy. Another group includes those who used antibiotics frequently and those who have esophageal motility disorder (cardiac achalasia and scleroderma). Patients complained of pain on swallowing, difficulty swallowing, and pain behind the sternum. On physical examination, there is a plaque that often occurs together with oral thrush. Endoscopic examination is the best approach to diagnose this disease by directly observing the white mucosal plaque-like lesions and exudates adherent to the mucosa. These adherent lesions cannot be washed off with water from irrigation. This disease is confirmed histologically by taking the biopsy or brushings of yeast and pseudohyphae invading mucosal cells. The treatment is by systemic antifungal drugs given orally in a defined course. It is important to differentiate esophageal candidiasis from other forms of infectious esophagitis such as cytomegalovirus, herpes simplex virus, gastroesophageal reflux disease, medication-induced esophagitis, radiation-induced esophageal injury, and inflammatory conditions such as eosinophilic esophagitis. Except for a few complications such as necrotizing esophageal candidiasis, fistula, and sepsis, the prognosis of esophageal candidiasis has been good.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854261PMC
http://dx.doi.org/10.1155/2019/3585136DOI Listing

Publication Analysis

Top Keywords

esophageal candidiasis
20
infectious esophagitis
8
esophageal
7
candidiasis
5
diagnosis treatment
4
treatment esophageal
4
candidiasis current
4
current updates
4
updates esophageal
4
candidiasis common
4

Similar Publications

Article Synopsis
  • The study aimed to investigate the relationship between the histological characteristics of esophageal candidiasis and various clinical factors, highlighting instances where inflammation might not be present.
  • A review of 53 biopsy specimens revealed that acute inflammation was absent in about 38% of cases, and smoking significantly correlated with this absence of inflammation.
  • Findings suggest that smokers may experience a unique immunosuppressive effect in relation to esophagitis, as the inflammation was often missing in their biopsies compared to non-smokers.
View Article and Find Full Text PDF

Introduction: Tuberculosis (TB) remains the most common opportunistic infection and leading cause of death among individuals living with HIV/AIDS in Ethiopia. Its significant impact on morbidity and mortality underscores the crucial link between these two diseases. While the advent of antiretroviral therapy (ART) has led to a dramatic decline in mortality rates among HIV/AIDS patients, TB continues to pose a substantial threat.

View Article and Find Full Text PDF

Background And Aims: Budesonide orodispersible tablets (BOT) have been shown to be safe and effective in phase 3 double-blind trials of induction and 48-week maintenance therapy of eosinophilic esophagitis (EoE). We now analyzed the long-term efficacy and safety of BOT in a 96-week open-label extension (OLE) study.

Methods: All EoE patients in the 48-week double-blind maintenance study were eligible to receive BOT treatment for up to 96 weeks.

View Article and Find Full Text PDF
Article Synopsis
  • * A 78-year-old male with dysphagia underwent several diagnostic procedures, ultimately confirming a diagnosis of diffuse large B-cell lymphoma (DLBCL) after various initial findings were misattributed to less severe conditions.
  • * The rapid progression of the disease in this patient underscored the need for prompt recognition of primary oesophageal lymphoma, especially in older individuals, and ultimately shifted the focus to palliative care due to the aggressive nature of the illness.
View Article and Find Full Text PDF

Background: EsoCap is a thin mucoadhesive film designed to target the oesophageal mucosa. The device loaded with mometasone furoate (ESO-101) is under investigation for the treatment of eosinophilic oesophagitis (EoE).

Aims: To evaluate the efficacy, safety and tolerability of ESO-101 in patients with active EoE.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!